Full Press Release Details
Cautionary note regarding forward-looking statements This presentation
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project,"
"should," "target," "will," or "would" or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances
of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: preclinical and clinical development of Viridian's product
candidates VRDN-001, VRDN-003, VRDN-006 and VRDN-008; enrollment in Viridian's clinical studies; upcoming milestones and potential data results, including topline results; the potential utility, efficacy, potency, safety, clinical benefits,
clinical response and activity, treatment burden and convenience of VRDN-001, VRDN-003, VRDN-006 and VRDN-008; that VRDN-001 has the potential to improve patient experience with a differentiated dosing regimen and reduce treatment burden to
patients; the time to market and commercial viability of Viridian's product candidates; potential market sizes and market opportunities, including for Viridian's product candidates; later-entrant subcutaneous therapies having the
potential to expand the market and take market share from incumbent IV; Viridian's product candidates potentially being best-in-class; anticipated start dates and designs of studies, including the VRDN-003 pivotal program and clinical trials
REVEAL-1 and REVEAL-2; VRDN-003 SC dosing regimens being predicted to achieve exposure levels associated with VRDN-001 IV clinical activity; potential dosing regimens and trial designs; core clinical packages to support registration; plans for a
commercial launch of VRDN-003 with an auto-injector; alignment with regulatory authorities and anticipated regulatory submissions, including the anticipated BLA submissions for VRDN-001 and VRDN-003 and the anticipated IND submission for VRDN-006;
and Viridian's cash runway lasting into the second half of 2026. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied)
are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: the potential utility, efficacy, potency, safety, clinical
benefits, clinical response and activity, treatment burden and convenience of Viridian's product candidates; the relationship between the results from the positive data from completed or ongoing clinical trials and the results of ongoing or
future clinical trials; that preliminary data may not be representative of final data; the timing, progress and plans for our ongoing or future research, preclinical and clinical development programs; trial protocols for ongoing clinical trials;
regulatory interactions; expectations regarding the timing for regulatory filings; expectations regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of
regulatory delays in our clinical programs; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; manufacturing and supply chain risks; competition from other therapies or products; estimates of
market size; other matters that could affect the sufficiency of existing cash, cash equivalents and short-term investments to fund operations; our financial position and its projected cash runway; our future operating results and financial
performance; Viridian's intellectual property position; and the timing of preclinical and clinical trial activities and reporting results from same. These and other risks, uncertainties and important factors are described in the section
entitled "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 8, 2024 and our other subsequent disclosure documents filed with the SEC. The forward-looking statements in this
presentation represent our views as of the date of this presentation. Neither we, nor our affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. This presentation also contains
estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such
estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. 2
Viridian is building upon proven first market entrants to develop
differentiated next-generation products that benefit patients Identify market opportunities with clear remaining unmet need Determine key areas of potential product differentiation First-generation product establishes significant opportunity for
next-generation strategy Engineer potential best-in-class antibodies and therapeutic proteins Rapidly advance programs to patients 3
Differentiated pipeline: late-stage Thyroid Eye Disease programs and
preclinical FcRn portfolio DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 VRDN-001 Thyroid Eye Intravenous Disease (anti-IGF-1R) On track to Portfolio VRDN-003 initiate Phase 3 Subcutaneous in August 2024 VRDN-006 FcRn-targeting Fc fragment
FcRn-Targeting Autoimmune Portfolio VRDN-008 Extended half-life FcRn inhibitor 4 FcRn = neonatal Fc receptor, IGF-1R = insulin-like growth factor-1 receptor, TED = thyroid eye disease.
Significant progress in 2024 to date - All catalysts on track
Anticipated Catalysts THRIVE topline: Sept. 2024 THRIVE: completed and exceeded enrollment in March VRDN-001 THRIVE-2 topline: Year-end 2024 THRIVE-2: enrollment target reached; topline data on track for year- Intravenous end 2024
VRDN-001 BLA: 2H 2025 REVEAL-1 & REVEAL-2 Positive FDA Type C meeting completed initiation: Aug. 2024 VRDN-003 Topline data: 1H 2026 Phase 3 REVEAL-1 and REVEAL-2 clinical trials planned in Subcutaneous active and chronic TED
VRDN-003 BLA: Year-end 2026 VRDN-006: IND by year-end 2024 FcRn 2H 2024 catalysts remain on track Portfolio VRDN-008: NHP data in 2H 2024 $613.2M cash as of March 31, 2024; runway into 2H 2026 Financial 5 BLA = Biologics License
Application, FDA = Food and Drug Administration, IND = Investigational New Drug, NHP = non-human primate.
Thyroid Eye Disease (TED) Portfolio 6
TED is an autoimmune condition characterized by inflammation, growth,
and damage to tissues around and behind the eyes Normal Eye Anatomy Thyroid Eye Disease (TED) 1 Autoantibodies trigger IGF-1R/TSHR pathway Bulging Eyes Heterogeneous autoimmune disease with clinical signs and symptoms that can vary or modulate
following onset, 2,3 in some cases for the rest of a patient's life Main signs include proptosis (eye bulging), redness, 2,3 Optic Nerve Enlargement of extraocular muscles swelling, diplopia (double vision), and lid retraction People living
with TED experience proptosis, redness, swelling, diplopia, Severe cases can cause sight-threatening optic and lid retraction 4 nerve compression An estimated 190K people in the US alone have 5 moderate to severe TED 1 2 3 4 Sources: George A et al.
Front. Endocrinol. 11:629925 (2021), Smith TJ et al. NEJM. 2016;375(16):1552-1565., Bahn RS. NEJM. 2010; 326(8): 726-738., Bartley GB et al. Am J Ophthalmol 1996;121:284-90., 5 Viridian-sponsored market research, includes active and chronic
TED. TED patient images are from NEJM, Bahn RS, Graves Ophthalmopathy, 362(8): 726-738. Copyright (2010) Massachusetts Medical Society. 7 Reprinted with permission from Massachusetts Medical Society. IGF-1R = insulin-growth factor 1 receptor,
TED = thyroid eye disease, TSHR = thyroid stimulating hormone receptor.
Anti-IGF-1R is the only approved targeted mAb treatment for TED 1
Anti-IGF-1R is the only targeted mechanism approved for TED VALIDATED TARGET WITH PROVEN EFFICACY Both active and chronic TED patients demonstrate 2,3 substantial benefit regardless of disease duration 2,3 In teprotumumab clinical studies:
WELL-ESTABLISHED - Majority of AEs were mild SAFETY PROFILE - AEs are generally transient & reversible 4 Interviewed treating physicians cite comfort with managing AEs 5 More than 15k TED patients have received teprotumumab to date 1
2 3 4 5 Teprotumumab Prescribing Information; Douglas RS et al. N Engl J Med. 2020. Douglas RS, et al. Clin Endocrinol Metab. 2024. Viridian market research on file, TEPEZZA (teprotumumab-trbw) Patient Website AEs = Adverse Events, IGF-1R =
insulin-like growth factor-1 receptor, TED = Thyroid Eye Disease 8
TED represents a large market opportunity for novel differentiated
treatments and global growth potential Teprotumumab Large Market with Limited Options Primed for New Entrants and Growth Net Sales (US) 1 ~$1.8 B ~190k people with moderate-to-severe New-Start Market - every patient is a new 2
TED in the US alone patient regardless of time of diagnosis Opportunity to treat active and chronic TED; no 3 maintenance treatment to disrupt ~15k TED patients treated to date with IV teprotumumab, the only 5 approved targeted therapy
Need for Lower Treatment Burden : - VRDN-001 potential to lower IV burden with ~70% High Burden of Treatment: Teprotumumab 6 less total time in chair 4 requires 8 infusions; one every three weeks ; requires visits to infusion
center which may - SC VRDN-003 potential to transform patient convenience and increase patient access not be convenient for many patients 2023 Significant ex-US markets with large, 2,5 underserved TED patient population Significant
opportunity remains for novel therapies to overcome the burden of current TED therapy and address the outstanding unmet need 1 2 3 Sources: Amgen Q4 2023 filings, Horizon Q1-Q3 2023 SEC filings, Viridian analysis including Viridian-sponsored market
research, includes active and chronic TED, TEPEZZA (teprotumumab-trbw) Patient 4 5 6 Website, Teprotumumab Prescribing Information, Viridian-sponsored market research, Viridian internal analysis 9 IGF-1R = insulin-like growth factor-1
receptor, IV = intravenous, SC = subcutaneous, TED = thyroid eye disease.
Building upon a proven MOA with demonstrated efficacy, Viridian is
developing two differentiated anti-IGF-1R mAbs VRDN-001 (IV) VRDN-003 (SC) VRDN-001 and VRDN-003 have the same binding domain VRDN-003 is engineered for a longer half-life, shown to be 40-50 days in a HV study, 4-5x that of
VRDN-001 Source: Viridian data on file. 10 IGF-1R = insulin-like growth factor-1 receptor, IV = intravenous, mAbs = monoclonal antibodies, MOA = mechanism of action, SC = subcutaneous, HV = healthy volunteers.
VRDN-001 Intravenous anti-IGF-1R 11
Phase 2: VRDN-001 in active TED showed robust clinical activity after
two infusions in all dose cohorts Signs Symptoms Improvement in Improvement in Clinical Activity proptosis Score (CAS) and diplopia score Overall response: Proptosis: Proptosis: CAS*: CAS*: Diplopia: Signs + symptoms Responder rate Mean change by
Score of 0 or 1 Mean change Complete exophthalmometry resolution** (Improvement in (% with 2mm (% achieving CAS of (change from proptosis & clinical reduction from 0 or 1 at week 6) baseline to week 6) (change from (% improved to a
activity score) baseline to week 6) baseline to week 6) score of 0 at week 6) VRDN-001 (Active TED Phase 2 Trial 67% 71% -2.3 mm 62% -4.1 54% Cohorts: 3, 10 or 20 mg/kg; week 6 after two doses) n=21 3 mg/kg / 10 mg/kg / 20 mg/kg -2.7 -2.4 -1.7 56%
83% 67% 67% 83% 67% 67% 83% 33% -4.2 -4.3 -3.7 20% 75% 75% n=9 n=6 n=6 mm mm mm Teprotumumab clinical 1,2,3 data (separate study) 44% 56% -1.9 mm 22% -2.1 36% (at 10 mg/kg 20 mg/kg; Week 6 after two doses) These data do not represent results
of a head-to-head comparative study of teprotumumab against VRDN-001. Comparing data across studies is not reliable due to many factors, including differences in trial design, subject characteristics, and data collection and analysis techniques.
Preliminary data are as of data cut-off of December 19, 2023. *Clinical Activity Score (CAS) = a composite 0-7 scale scoring signs and symptoms of TED. **Diplopia was present at baseline in 13 out of 21 drug-treated patients; 4 in 10 and 20 mg/kg
dose cohort, 5 in the 3 mg/kg cohort. 1 2 Sources: Viridian clinical data on file. Teprotumumab Phase 3 data: Douglas RS, et al, NEJM 382:4, Jan 2020, Douglas RS, et al, Ophthalmology 129:4, Apr 2022., FDA clinical review of teprotumumab BLA
completed Jan 3 13, 2020., Horizon briefing book for teprotumumab to support BLA, Nov 9, 2019. 12 CAS = Clinical Activity Score, IV = intravenous, TED = thyroid eye disease.
Phase 2: VRDN-001 IV was well tolerated in active TED VRDN-001 3 mg/kg,
10 mg/kg, & 20 mg/kg TED cohorts VRDN-001 VRDN-001 VRDN-001 Placebo 3 mg/kg 10 mg/kg 20 mg/kg (n=5), n (n=9), n (n=6), n (n=6), n Adverse Reactions: Muscle spasms 2 2 2** - 2 - - - Nausea - - - 1 Alopecia No serious adverse Diarrhea 1 2** 1* -
events (SAEs), - 1 - 3 Fatigue no infusion reactions, Hyperglycemia 1 - 1* - and no discontinuations in patients treated with 1 1 - - Hearing impairment VRDN-001 - - 1 - Dysgeusia Headache 2 1 1 2** 1 - 1 - Dry skin Infusion reactions - - - - Safety
profile generally consistent across 3, 10, and 20 mg/kg cohorts; no SAEs or infusion reactions Preliminary data are as of data cut-off of December 19, 2022. * Deemed unrelated to study drug by the masked investigator ** One patient deemed related
and one patient deemed unrelated to study drug by the masked investigators. Other AE that occurred in more than one patient and deemed related to study drug by masked investigators was acne (n=2). Instances were mild and did not require
intervention. Muscle spasms were mild and 13 did not require intervention; hearing impairment (n=2) resolved without intervention in both cases. Both patients with hyperglycemia were diabetic at baseline; in 1 case glucose variability was determined
by masked PI to be unrelated to drug. Sources: Viridian clinical data on file. IV = intravenous, TED = thyroid eye disease, SAEs = serious adverse events.
Phase 2: VRDN-001 IV in chronic TED showed robust clinical activity
after two infusions in both dose cohorts Symptoms Signs Improvement in Clinical Activity Improvement in proptosis Score (CAS) and diplopia score Proptosis: Proptosis: Proptosis: CAS: CAS: Diplopia: Responder rate Mean change by Mean change by Score
of 0 or 1** Mean change** Complete exophthalmometry MRI* resolution*** (% with 2 mm (% achieving CAS of (baseline to week 6) reduction baseline to 0 or 1 at week 6) (baseline to week 6) (baseline to week 6) (% improved to a Patients CAS>0
at week 6) score of 0 at week 6) Excludes Patients baseline CAS=0 at baseline VRDN-001 (Chronic TED Phase 2 Cohorts: 42% -1.6 mm -2.0 mm 40% -2.3 0% 10 and 3 mg/kg; week 6 after two doses) n=12 10 mg/kg / 3 mg/kg -1.8 -1.5 -1.5 -2.6 50% 33% 50% 33%
-2.8 -2.0 0% 0% n=6 n=6 mm mm mm mm Teprotumumab clinical 1 data (separate study) 36% -1.17 mm Not reported Not reported Not reported Not reported (at 10 mg/kg 20 mg/kg; week 6 Teprotumumab study limited enrollment to patients after two
doses) with low CAS scores (0 or 1); VRDN-001 study did not limit enrollment based on CAS score These data do not represent results of a head-to-head comparative study of teprotumumab against VRDN-001. Comparing data across studies is not reliable
due to many factors, including differences in trial design, subject characteristics, and data collection and analysis techniques. Preliminary data are as of data cut-off of May 30, 2023. *MRI available for 4 of 6 VRDN-001 10 mg/kg treated patients,
4 of 6 VRDN-001 3 mg/kg treated patients. **2 patients with CAS of 0 at baseline excluded from calculation. ***Includes only participants who had diplopia present at baseline. Diplopia was present at baseline in 5 of 12 VRDN-001 treated patients; 2
in 3 14 mg/kg cohort, and 3 in 10 mg/kg cohort. 1 Sources: Viridian clinical data on file. Douglas RS, et al. Clin Endocrinol Metab. 2023 Oct 31:dgad637. CAS = clinical activity score IV = intravenous, MRI = magnetic resonance imaging, TED = thyroid
Phase 2: VRDN-001 IV was well tolerated in chronic TED Reported adverse
events occurring in 10% of patients VRDN-001 Placebo 10 & 3 mg/kg (n=5), n (n=13*), n Back pain 2 (15%) 0 (0%) 2 (15%) 0 (0%) Muscle spasms 1 (8%) 2 (40%) Headache Ear discomfort 0 (0%) 1 (20%) 0 (0%) 1 (20%) Fatigue 0 (0%) 1 (20%)
Flatulence Pruritus 0 (0%) 1 (20%) No serious adverse events (SAEs); no hearing impairment or hyperglycemia events th Preliminary data are as of data cut-off of May 30, 2023. *Though not evaluable at week 6 for clinical activity, the 7 patient
randomized in the 3 mg/kg cohort who discontinued the trial prior to week 6 due to leaving the 15 country for a family emergency was followed for safety until their discontinuation. Source: Viridian clinical data on file. IV = intravenous, TED =
thyroid eye disease, SAEs = serious adverse events.
Phase 3 THRIVE (active) and THRIVE-2 (chronic) are on track to deliver
topline results this year ACTIVE TED Enrollment Complete CHRONIC TED Enrollment Target Reached & Completion Expected in July Key Inclusion Criteria Key Inclusion Criteria >40% enrollment from the US Proptosis of 3 mm
Proptosis of 3 mm CAS 3 Any CAS (0-7) Onset of TED symptoms within 15 months Onset of TED symptoms >15 months Trial Design Trial Design N = 90 (actual enrollment: 113 patients) N =
approx.159 (expect to exceed enrollment target) 15-week primary endpoint, 52-week total follow-up 15-week primary endpoint, 52-week total follow-up Double-masked, randomized, placebo-controlled Double-masked,
randomized, placebo-controlled Topline results expected Sept. 2024 Topline results expected year-end 2024 Global study of VRDN-001 in TED patients to meet safety database requirement for planned 2H 2025 BLA filing STRIVE Broad
patient inclusion criteria (any severity or duration of disease) and an active control arm (no placebo) 16 BLA = Biologics License Application, CAS = clinical activity score, TED = thyroid eye disease.
VRDN-001 has the potential to improve patient experience with a
differentiated dosing regimen 1 VRDN-001 Teprotumumab Potential Viridian 2 Differentiators Mechanism Same target & MOA; more complete IGF-1R full antagonist IGF-1R partial antagonist of Action receptor inhibition with VRDN-001 Treatment 5
infusions given 8 infusions given ~2/3 less volume infused Regimen every 3 weeks every 3 weeks 20 mg/kg for Dose 10 mg/kg each dose 7 infusions after ~2/3 less drug exposure 10 mg/kg loading dose Infusion Time 30 minutes 60-90 minutes ~70%
less total time in chair Potential for reduced treatment burden to patients 1 2 Sources: Teprotumumab Prescribing Information; Viridian internal analysis on file 17 IGF-1R = insulin-like growth factor-1 receptor; MOA = mechanism of